Gallium IV study for adults with cystic fibrosis and NTM lung infection
Part of Digestive system, Genetic & congenital, Infections, Lungs & breathing clinical trials.
This Phase 1 study tests whether an IV medicine called gallium can treat hard-to-treat lung infections (NTM) in adults with cystic fibrosis. It is mainly for people who have not been treated yet for NTM or who have NTM that has not cleared despite antibiotics.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older and able to consent (or have a legal representative consent)
- Have a cystic fibrosis diagnosis and ongoing NTM lung infection on repeat sputum/BAL cultures
- Have NTM cultures showing the same type/species (M. avium complex and/or M. abscessus complex) over time
- Either no prior NTM treatment that cleared the infection (or treatment that did not clear it for long periods, depending on which group you’re in)
- Lung function at screening must be at least 25% predicted (FEV1 ≥ 25%)
- Be able to cough up sputum and be medically stable (no major health changes) in the week before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special virus therapy (phage) can help clear stubborn NTM lung infections in people with cystic fibrosis who have been on antibiotics for over a year without success. Participants will continue their antibiotics while receiving the phages.
This study looks at whether a urine test (instead of repeated sputum—mucus—from the lungs testing) can help determine who with cystic fibrosis does not have certain lung germs called NTM. If the urine test works, it could reduce the need for lung sample testing while still keeping people safe.
This study follows people with a newly diagnosed MAC lung infection (a specific type of mycobacterial disease) and tests how they do on the standard three-drug treatment plan. It may help researchers better understand outcomes and safety for this condition.
This trial follows people with cystic fibrosis to better understand how “nontuberculous mycobacteria” (a type of lung germ) spreads between healthcare visits and care settings. It may help improve future prevention and monitoring strategies for CF patients who have had these bacteria.
This study looks at whether people with cystic fibrosis (CF) can pick up nontuberculous mycobacteria (NTM) from their home environment. It compares homes of people with CF who have NTM to those who don't, to see where germs might be hiding.
This study looks at the community of tiny organisms in the lungs (the lung microbiome) in people with bronchiectasis caused by NTM (non-tuberculous mycobacteria). It compares people with positive NTM cultures to people without, to better understand what’s going on in the lungs and why symptoms may differ.
Hear when a new Nontuberculous Mycobacterium Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.